Pulse Biosciences Stock Investor Sentiment

PLSE Stock  USD 17.82  0.90  4.81%   
About 55% of Pulse Biosciences' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Pulse Biosciences stock suggests that some investors are interested at this time. The current market sentiment, together with Pulse Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pulse Biosciences stock news signals to limit their universe of possible portfolio assets.
  

Pulse Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulse Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pulse Biosciences Maximum Pain Price Across April 17th 2025 Option Contracts

Pulse Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Pulse Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Pulse Biosciences' options.
over a year ago at www.macroaxis.com         
Exercise or conversion by Zanganeh Mahkam of 20000 shares of Pulse Biosciences subject to Rule 16b-3
Macroaxis News
over a year ago at finance.yahoo.com         
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
Yahoo News
over a year ago at news.google.com         
Earnings call Pulse Biosciences showcases progress in Q3 2023 ... - Investing.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Pulse Biosciences, Inc. Q3 2023 Earnings Call Transcript
Yahoo News
over a year ago at insidermonkey.com         
Pulse Biosciences, Inc. Q3 2023 Earnings Call Transcript
insidermonkey News
over a year ago at finance.yahoo.com         
Pulsed Field Ablation Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce ...
Yahoo News
over a year ago at investing.com         
Earnings call Pulse Biosciences showcases progress in Q3 2023, eyes cardiac ablation market with Cel...
Investing News at Macroaxis
over a year ago at news.google.com         
Pulse Biosciences Reports Business Updates and Third Quarter ... - BioSpace
Google News at Macroaxis
over a year ago at gurufocus.com         
Pulse Biosciences Inc Reports Decrease in Q3 Losses and Advances in Cardiac Device ...
Gurufocus Stories at Macroaxis
over a year ago at businesswire.com         
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
businesswire News
over a year ago at finance.yahoo.com         
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
Yahoo News
over a year ago at news.google.com         
Earnings call Summit Therapeutics highlights progress in ... - Investing.com
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Acquisition by Darrin Uecker of 330000 shares of Pulse Biosciences subject to Rule 16b-3
Macroaxis News
over a year ago at businesswire.com         
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 20...
businesswire News
over a year ago at news.google.com         
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery - Yahoo Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pulse Biosciences that are available to investors today. That information is available publicly through Pulse media outlets and privately through word of mouth or via Pulse internal channels. However, regardless of the origin, that massive amount of Pulse data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulse Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulse Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulse Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulse Biosciences alpha.

Pulse Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Zanganeh Mahkam of 200000 shares of Pulse Biosciences at 15.65 subject to Rule 16b-3
11/05/2024
2
How to Take Advantage of moves in - Stock Traders Daily
11/19/2024
3
Acquisition by Robert Duggan of 6054 shares of Pulse Biosciences at 16.74 subject to Rule 16b-3
12/11/2024
4
Top Key Executive Robert Duggan, Pulse Biosciences, Inc.s largest shareholder sees value of holdings go down 13 percent after recent drop
12/12/2024
5
Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3
12/13/2024
6
Executive Co-Chairman of Pulse Biosciences Robert Duggan Buys More Stock
12/16/2024
7
Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3
12/18/2024
8
Pulse Biosciences Triggers 66M Warrant Redemption After Stock Price Surge Above 16.50 PLSE Stock News - StockTitan
12/23/2024
9
Acquisition by Paul LaViolette of 450000 shares of Pulse Biosciences at 18.43 subject to Rule 16b-3
01/08/2025
10
Pulse Biosciences picks former Boston Scientific exec as new CEO
01/10/2025
11
Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
01/13/2025
12
Pulse Biosciences is on track for IDE study of PFA tech this year
01/21/2025

Complementary Tools for Pulse Stock analysis

When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators